749928-16-3

Basic information

• Product Name: Methanesulfonamide, N-[(1R)-1-(4-bromophenyl)ethyl]-
• CAS NO: 749928-16-3
• Molecular Formula: C9H12BrNO2S
• Molecular Weight: 278.17
• Mol File: 749928-16-3.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: Methanesulfonamide, N-[(1R)-1-(4-bromophenyl)ethyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Methanesulfonamide, N-[(1R)-1-(4-bromophenyl)ethyl]-(749928-16-3)
• EPA Substance Registry System: Methanesulfonamide, N-[(1R)-1-(4-bromophenyl)ethyl]-(749928-16-3)

Safety Data

• Hazardous Substances Data: 749928-16-3(Hazardous Substances Data)

Upstream product

• 24358-62-1 (R)-1-(4-bromophenyl)ethylamine 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 1449275-11-9 N-[(1R)-1-(4-acetylphenyl)ethyl]methanesulfonamide 
• 1449275-13-1 N-[(1R)-1-(4-{[(2S)-2-(4-fluorophenyl)morpholin-4-yl]methyl}phenyl)ethyl]methanesulfonamide 
• 1448682-03-8 N-[(1R)-1-(4-formylphenyl)ethyl]methanesulfonamide 

Relevant articles and documents

NOVEL BENZYL SULFONAMIDE COMPOUNDS USEFUL AS MOGAT-2 INHIBITORS

The present invention provides compounds of Formula I. Wherein Rl, L, and A are as described herein, or a pharmaceutical salt thereof, processes for preparing the compounds, and methods of treating a condition, such as hypertriglyceridemia, using the comp

NOVEL MORPHOLINYL DERIVATIVES USEFUL AS MOGAT-2 INHIBITORS

The present invention provides compounds of Formula I or a pharmaceutical salt thereof, methods of treating hypertriglyceridemia using the compounds; and a process for preparing the compounds.

INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME

The present invention provides compounds of formula (4), and their pharmaceutically acceptable salts and solvates, which are useful as inhibitors of the Hepatitis C virus (HCV) polymerase enzyme and are also useful for the treatment of HCV infections in HCV-infected mammals. The present invention also provides pharmaceutical compositions comprising compounds of formula (4), their pharmaceutically acceptable salts and solvates. Furthermore, the present invention provides intermediate compounds and methods useful in the preparation of compounds of formula (4).